Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Top 4 Wholesalers on Solid Note with 30% Operating Profit Rise in FY2022
Japan’s Big 4 pharma wholesalers delivered growth in both combined sales and profits in the fiscal year ended March 2023, staging a further recovery from the period hardest hit by COVID-19. However, there are uncertainties over whether this trend will…
To read the full story
Related Article
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
- Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
November 18, 2025
- Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
- Japan’s Big 4 Drug Wholesalers Log 17.6% Operating Profit Growth
November 18, 2024
- Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
- Change in Dynamics? Suzuken Emerges as No. 2 among Big 4 Japan Wholesalers
November 15, 2023
- Top 4 Wholesalers on Recovery Trend, Operating Profit Up 69.1% in April-September
November 16, 2022
BUSINESS
- Parexel Revs Up AI Drive, Targets 6-Month Trial Time Cut
October 8, 2026
- FDA Accepts BridgeBio’s Infigratinib NDA for Achondroplasia
October 8, 2026
- Eylea 8 mg Shows Vision Gains in 24-Week Analysis
October 8, 2026
- Boehringer, Hiroshima Tie Up on Health Promotion
October 8, 2026
- Japan Ethical Drug Sales Up 3% in August: Crecon
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…